||CsnPharm

CAS No.: 262352-17-0

Torcetrapib/托彻普 Catalog No. CSN12117

Synonyms: CP-529414;CP-529,414;托彻普

Torcetrapib is a CETP inhibitor with IC50 of 37 nM, elevates HDL-C and reduces nonHDL-C in plasma.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述Torcetrapib is a CETP inhibitor with IC50 of 37 nM, elevates HDL-C and reduces nonHDL-C in plasma.
临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00136981	Hypercholesterolemia, Familial... more >> Hyperlipidemia Collapse <<	Phase 3	Completed	-	-
NCT00134173	Coronary Disease ... more >> Coronary Arteriosclerosis Hyperlipidemia Collapse <<	Phase 3	Completed	-	-
NCT00134238	Mixed Hyperlipidemia	Phase 3	Terminated	-	-

更多
参考文献

[1] Hu X, Dietz JD, et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology. 2009 May;150(5):2211-9.
[2] Clark RW, Sutfin TA, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):490-7.

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 1.6654 mL
- 8.3268 mL
- 16.6535 mL
- 5 mM
- 0.3331 mL
- 1.6654 mL
- 3.3307 mL
- 10 mM
- 0.1665 mL
- 0.8327 mL
- 1.6654 mL

技术信息

CAS号	262352-17-0	储存条件	粉末液体 -20°C:3-6 月 -80°C:12月
分子式	C26H25F9N2O4	运输	蓝冰
分子量	600.47	别名	CP-529414;CP-529,414;托彻普

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT00136981	Hypercholesterolemia, Familial... more >> Hyperlipidemia Collapse <<	Phase 3	Completed	-	-
NCT00134173	Coronary Disease ... more >> Coronary Arteriosclerosis Hyperlipidemia Collapse <<	Phase 3	Completed	-	-
NCT00134238	Mixed Hyperlipidemia	Phase 3	Terminated	-	-
NCT00137462	Hyperlipidemia	Phase 3	Completed	-	-
NCT00452842	-	-	Terminated(See termination rea... more >>son in detailed description.) Collapse <<	-	United States, Florida ... more >> Pfizer Investigational Site Clearwater, Florida, United States, 33756 Collapse <<
NCT00138762	Hyperlipidemia	Phase 3	Completed	-	-
NCT00267280	Hyperlipidemia ... more >> Dyslipidemia Hypercholesterolemia Collapse <<	Phase 3	Terminated	-	-
NCT00267254	Hyperlipidemia ... more >> Dyslipidemia Hypercholesterolemia Collapse <<	Phase 3	Completed	-	-
NCT00134498	Hypertriglyceridemia ... more >> Hyperlipoproteinemia Type IV Collapse <<	Phase 3	Completed	-	-
NCT00134485	Hypercholesterolemia, Familial... more >> Hyperlipidemia Collapse <<	Phase 3	Completed	-	-
NCT00145431	Hyperlipoproteinemia Type III	Phase 3	Terminated	-	-
NCT00267267	Hyperlipidemia ... more >> Dyslipidemia Collapse <<	Phase 3	Terminated	-	-
NCT00134511	Hypercholesterolemia, Familial	Phase 3	Completed	-	United States, Massachusetts ... more >> Pfizer Investigational Site Boston, Massachusetts, United States, 02114 Canada, Quebec Pfizer Investigational Site Chicoutimi, Quebec, Canada, G7H 5H6 Pfizer Investigational Site Ste-Foy, Quebec, Canada, G1V 4M6 South Africa Pfizer Investigational Site Parktown, Johannesburg, South Africa, 2193 Pfizer Investigational Site Bloemfontein, South Africa, 9301 Pfizer Investigational Site Cape Town, South Africa, 7925 Collapse <<
NCT00139061	Hyperlipidemia	Phase 3	Completed	-	France ... more >> Pfizer Investigational Site Angers, France, 49 000 Pfizer Investigational Site Angers, France, 49 100 Pfizer Investigational Site Bordeaux Cauderan, France, 33 200 Pfizer Investigational Site Briollay, France, 49125 Pfizer Investigational Site Dijon, France, 21000 Pfizer Investigational Site Hagondange, France, 57 300 Pfizer Investigational Site Haut Mauco, France, 40 280 Pfizer Investigational Site Jarny, France, 54800 Pfizer Investigational Site Lille, France, 59 037 Cedex Pfizer Investigational Site Mars LA Tour, France, 54800 Pfizer Investigational Site Metz, France, 57070 Pfizer Investigational Site Monguilhem, France, 32 240 Pfizer Investigational Site Mont de Marsan CEDEX, France, 40010 Pfizer Investigational Site Mont de Marsan, France, 40 010 cedex Pfizer Investigational Site Mont de Marsan, France, 40 010 Pfizer Investigational Site Mont de Marsan, France, 40000 Pfizer Investigational Site Moutiers, France, 54660 Pfizer Investigational Site Murs Erigne, France, 49610 Pfizer Investigational Site Nantes, France, 44 093 Cedex 01 Pfizer Investigational Site Pouilly en Auxois, France, 21 850 Pfizer Investigational Site Saint Justin, France, 40 240 Pfizer Investigational Site Saint Martin D'Oney, France, 40090 Pfizer Investigational Site Seysses, France, 31600 Pfizer Investigational Site Strasbourg, France, 67000 Pfizer Investigational Site Thouars, France, 79100 Pfizer Investigational Site Tierce, France, 49 125 Collapse <<
NCT00134264	Coronary Disease ... more >> Diabetes Mellitus Collapse <<	Phase 3	Terminated	-	-

Torcetrapib/托彻普 Catalog No. CSN12117

靶点选择性

请登录您的专属账户

确认信息